7.6 C
New York
Sunday, April 2, 2023

Are Things Looking Up For Zymeworks Inc. (NASDAQ: ZYME)?

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Zymeworks Inc. (ZYME) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.17, or 2.13%, to $8.17. The Zymeworks Inc. has recorded 237 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Zymeworks Announces Participation in Upcoming Investor Conferences.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $8.00 and fluctuated between $8.08 as its day high and $7.42 as its day low. The current market capitalization of Zymeworks Inc. is $504.56M. A total of 0.62 million shares were traded on the day, compared to an average of 1.16M shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ZYME has seen 7 BUY and 2 SELL insider trades, representing the acquisition of 2,014,500 and the disposition of 1,774 shares. Over the last 12 months, there were 22 BUYs and 7 SELLs from insiders. Insiders purchased 2,111,373 shares during that period but sold 15,157.

In the most recent transaction, EcoR1 Capital, LLC bought 163,400 shares of ZYME for 9.88 per share on Jan 20. After the transaction, the 10% Owner now owns 9,887,473 company shares. In a previous transaction on Jan 19, EcoR1 Capital, LLC bought 144,100 shares at 9.49 per share. ZYME shares that 10% Owner owns now total 9,724,073.

Among the insiders who bought shares, EcoR1 Capital, LLC acquired of 203,000 shares on Jan 18 at a per-share price of $10.00. This resulted in the 10% Owner holding 9,579,973 shares of ZYME after the transaction. In another insider transaction, EcoR1 Capital, LLC bought 440,000 shares at $9.80 per share on Jan 17. Company shares held by the 10% Owner now total 9,376,973.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ZYME in the last 3 months, the mean price target is $13.73 with high estimates of $21.00 and low estimates of $8.00. In terms of 52-week highs and lows, ZYME has a high of $10.80 and a low of $4.11.

As of this writing, ZYME has an earnings estimate of $3.12 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of $7.75 per share and a lower estimate of -$0.75. The company reported an EPS of -$0.97 in the last quarter, which was -1.00% lower than expectations of -$0.96.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 11 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Hold with a score of 4.27. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles